Ask the Expert: Avastin for Recurrent Glioblastoma Multiforme

What is Avastin?

Avastin® (Bevacizumab) is the first and only biologic treatment approved by Health Canada for recurrent glioblastoma multiforme (GBM), which offers an additional treatment option for people with the disease.

How is Avastin administered?

Avastin is given as a single agent at 10 mg/kg intravenously, once every two weeks.

How does Avastin work?

Avastin directly targets the tumour by controlling its growth and extends survival with only a limited impact on quality of life.

Is Avastin approved by Health Canada?

Health Canada approved Avastin in March 2010 as treatment for recurrent GBM.

How do patients access Avastin?

The answer to this question depends on:

  • The province in which the patient lives: In British Columbia, Saskatchewan and Manitoba, there is public access for Avastin in recurrent GBM via provincial drug plans.
  • Whether the patient has private insurance that provides coverage for Avastin.

Beyond the provinces where there is provincial coverage, access to Avastin depends on the type of private insurance coverage each patient may have (often from an employer). Once prescribed Avastin by their oncologist, a patient will contact their insurance carrier to determine coverage.

Please note, however, reimbursement via private insurance coverage is often granted on a case-by-case basis and may not be guaranteed.

There is also a Roche Patient Assistance Program (RPAP) in place to help patients access Avastin.

How do patients connect with the RPAP program?

For reimbursement navigation and coordination, financial assistance and infusion support services, patients should work with their oncologist to enrol in RPAP or call the program directly, toll-free, at 1-888-748-8926, Monday to Friday, 8:00 am to 8:00 pm Eastern Standard Time. Patients can also visit the RPAP website for more information.

Find more information about how to access Avastin

What is the most recent information about Avastin?

New research about the brain tumour treatment Bevacizumab (Avastin®) was released at the recent American Society of Clinical Oncology (ASCO) 2013 Annual Meeting. Results were presented from two recent clinical trials focused on the treatment. Read our summary of the results.

Find more information about advocacy on behalf of a patient or advocacy in support of the brain tumour community in the advocacy section of the website.
Download this information as a Brain Tumour Foundation of Canada Information Sheet (pdf)

Return to Information Sheets here.

This information is provided for information purposes only, and do not represent advice, an endorsement or a recommendation, with respect to any product, service or business, and/or the claims and properties thereof, by Brain Tumour Foundation of Canada. Always consult your health care team if you have questions about your medical care and treatments options.

Share This

Featured Story

Team Barbie Walk at Hamilton Spring Sprint

Barb G. and her loved ones join the Hamilton Spring Sprint as “Team Barbie,” where they will walk to show their support for brain tumour survivors and patients across the country just like Barb.

Learn more

Spotlight

"We can all make a difference"

Barb C.: survivor, fundraiser, volunteer. Learn why she's involved with Spring Sprint......

Learn more

Brain Tumor Funders' Collaborative Project Update

Read the latest update on long-term survival in GBM...

Learn more

Upcoming Events

  • 27/Apr/2015: Greater Sudbury Support Group: Meets at Sudbury Public Library - Main Branch, 74 MacKenzie Street... Learn more >
  • 28/Apr/2015: Ottawa Support Group: Meets at the Maplesoft Centre at 1500 Alta Vista Drive, Ottawa, ON.... Learn more >
  • 01/May/2015: 2015 BrainCycle Tour: In memory of 'Uncle John' who passed away from a brain tumour in 2007.... Learn more >
  • 02/May/2015: Hamilton Spring Sprint: Dofasco Park: Opens at 10:00am... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2015 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001
Imagine Canada Ethical Code